Updates in the Treatment Landscape of AML
Eunice Wang, MD, discusses the new treatment era for patients with acute myeloid leukemia after the approval of 3 new treatment regimens at the end of 2018.
Eunice Wang, MD, chief of the leukemia service at the Roswell Park Comprehensive Cancer Center, discusses the new era of treatment for patients with acute myeloid leukemia (AML) afterthe approval of 3 new treatment regimensat the end of 2018.
With these approvals, physicians are questioning how necessary the standard backbone chemotherapy low-dose cytarabine and anthracycline-based treatments are; these agents have been the standard since the 1970s for younger and fitter patients.
For the last few years, physicians have been using low-dose hypomethylating agents for older patients. In the last year, there has been a breakthrough in terms of combination therapy with low-dose chemotherapy and oral agents.
FDA Clears IND for CT071 in RRMM and Primary Plasma Cell Leukemia
December 5th 2023CT071, a chimeric antigen receptor T-cell therapy candidate, had an investigational new drug application cleared by the FDA for patients with relapsed/refractory multiple myeloma and primary plasma cell leukemia.
Read More
Connecting Heart Disease and Hematologic Malignancies
November 28th 2023A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Read More
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
